Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol for Reactivating Cardiomyocyte Division in Tetralogy of Fallot
NCT04713657Phase 1Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2022
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in tetralogy of Fallot (TOF) and double outlet right ventricle (DORV) comparing Propranolol with Placebo (2 arms). Primary endpoint: Cardiomyocyte Division. Started Dec 2022; status: recruiting.
02
Drugs
propranolol
03
Conditions
tetralogy of Fallot (TOF)double outlet right ventricle (DORV)
Beyond the preview
Go deeper on NCT04713657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713657.